Skip to main content
Top
Published in: Breast Cancer Research 1/2016

Open Access 01-12-2016 | Research article

The impact of in situ breast cancer and family history on risk of subsequent breast cancer events and mortality - a population-based study from Sweden

Authors: Helena Sackey, Miao Hui, Kamila Czene, Helena Verkooijen, Gustaf Edgren, Jan Frisell, Mikael Hartman

Published in: Breast Cancer Research | Issue 1/2016

Login to get access

Abstract

Background

The clinical behavior of in situ breast cancer is incompletely understood and several factors have been associated with invasive recurrence. The purpose of this study was to evaluate long-term risk of subsequent breast cancer and mortality among women diagnosed with in situ breast cancer, in relation to family history

Methods

Using the population-based Swedish Multi-Generation and Cancer Registers we identified 8111 women diagnosed with in situ breast cancer between 1980 and 2004. We used standardized incidence ratios (SIRs) to measure the relative risk of subsequent invasive or contralateral in situ breast cancer and standardized mortality ratios (SMRs) for relative risks of death.

Results

Among women diagnosed with in situ breast cancer, the cumulative 10-year and 20-year risk for subsequent contralateral or ipsilateral invasive cancer was approximately 10 % and 18 %, respectively. The risk of subsequent invasive breast cancer was increased more than 4-fold (SIR 4.6 (95 % CI 4.2 − 4.9)) among women with in situ breast cancer as compared to women in the general population and the risk of contralateral in situ breast cancer was increased almost 16-fold (SIR 16.0 (95 % CI 13.2–19.1)). Having a family history of breast cancer increased the risk of contralateral invasive breast cancer by almost 50 % (incidence rate ratio 1.5 (95 % CI 1.0–2.0)). Women under forty years old at diagnosis, without family history, had a 7-fold increased risk, and those with a family history had a 14-fold increased risk for subsequent invasive breast cancer with SIRs of 7.2 (95 % CI 4.8–10.5) and 14.3 (95 % CI 7.4–25.0), respectively. The overall risk of death in women with in situ breast cancer was significantly increased by 30 % compared to the general population but was highly dependent on the occurrence of a second invasive cancer event (SMR 1.3 (95 % CI 1.2–1.4)).

Conclusions

Among women with in situ breast cancer, a positive family history increases the risk of contralateral invasive breast cancer by almost 50 %. The risk of subsequent invasive breast cancer and mortality is substantially higher in younger women, which should be taken into account when planning their treatment and follow up.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chuba PJ, Hamre MR, Yap J, Severson RK, Lucas D, Shamsa F, et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol. 2005;23(24):5534–41.CrossRefPubMed Chuba PJ, Hamre MR, Yap J, Severson RK, Lucas D, Shamsa F, et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol. 2005;23(24):5534–41.CrossRefPubMed
2.
go back to reference Erbas B, Provenzano E, Armes J, Gertig D. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat. 2006;97(2):135–44. Epub 2005/12/02. eng.CrossRefPubMed Erbas B, Provenzano E, Armes J, Gertig D. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat. 2006;97(2):135–44. Epub 2005/12/02. eng.CrossRefPubMed
3.
go back to reference Franceschi S, Levi F, La Vecchia C, Randimbison L, Te VC. Second cancers following in situ carcinoma of the breast. Int J Cancer. 1998;77(3):392–5. Epub 1998/07/15. eng.CrossRefPubMed Franceschi S, Levi F, La Vecchia C, Randimbison L, Te VC. Second cancers following in situ carcinoma of the breast. Int J Cancer. 1998;77(3):392–5. Epub 1998/07/15. eng.CrossRefPubMed
4.
go back to reference Innos K, Horn-Ross PL. Risk of second primary breast cancers among women with ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2008;111(3):531–40. Epub 2007/11/06. eng.CrossRefPubMed Innos K, Horn-Ross PL. Risk of second primary breast cancers among women with ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2008;111(3):531–40. Epub 2007/11/06. eng.CrossRefPubMed
5.
go back to reference Li CI, Malone KE, Saltzman BS, Daling JR. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988–2001. Cancer. 2006;106(10):2104–12. Epub 2006/04/11. eng.CrossRefPubMed Li CI, Malone KE, Saltzman BS, Daling JR. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988–2001. Cancer. 2006;106(10):2104–12. Epub 2006/04/11. eng.CrossRefPubMed
6.
go back to reference Robinson D, Holmberg L, Moller H. The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ. Br J Cancer. 2008;99(4):611–5. Epub 2008/07/31. eng.CrossRefPubMedPubMedCentral Robinson D, Holmberg L, Moller H. The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ. Br J Cancer. 2008;99(4):611–5. Epub 2008/07/31. eng.CrossRefPubMedPubMedCentral
7.
go back to reference Habel LA, Moe RE, Daling JR, Holte S, Rossing MA, Weiss NS. Risk of contralateral breast cancer among women with carcinoma in situ of the breast. Ann Surg. 1997;225(1):69–75. Pubmed Central PMCID: 1190608, Epub 1997/01/01. eng.CrossRefPubMedPubMedCentral Habel LA, Moe RE, Daling JR, Holte S, Rossing MA, Weiss NS. Risk of contralateral breast cancer among women with carcinoma in situ of the breast. Ann Surg. 1997;225(1):69–75. Pubmed Central PMCID: 1190608, Epub 1997/01/01. eng.CrossRefPubMedPubMedCentral
8.
go back to reference Rawal R, Lorenzo Bermejo J, Hemminki K. Risk of subsequent invasive breast carcinoma after in situ breast carcinoma in a population covered by national mammographic screening. Br J Cancer. 2005;92(1):162–6. Pubmed Central PMCID: 2361754, Epub 2004/12/01. eng.CrossRefPubMed Rawal R, Lorenzo Bermejo J, Hemminki K. Risk of subsequent invasive breast carcinoma after in situ breast carcinoma in a population covered by national mammographic screening. Br J Cancer. 2005;92(1):162–6. Pubmed Central PMCID: 2361754, Epub 2004/12/01. eng.CrossRefPubMed
9.
go back to reference Levi F, Randimbison L, Te VC, La Vecchia C. Invasive breast cancer following ductal and lobular carcinoma in situ of the breast. Int J Cancer. 2005;116(5):820–3. Epub 2005/04/20. eng.CrossRefPubMed Levi F, Randimbison L, Te VC, La Vecchia C. Invasive breast cancer following ductal and lobular carcinoma in situ of the breast. Int J Cancer. 2005;116(5):820–3. Epub 2005/04/20. eng.CrossRefPubMed
10.
go back to reference Warnberg F, Yuen J, Holmberg L. Risk of subsequent invasive breast cancer after breast carcinoma in situ. Lancet. 2000;355(9205):724–5. Epub 2000/03/07. eng.CrossRefPubMed Warnberg F, Yuen J, Holmberg L. Risk of subsequent invasive breast cancer after breast carcinoma in situ. Lancet. 2000;355(9205):724–5. Epub 2000/03/07. eng.CrossRefPubMed
11.
go back to reference Soerjomataram I, Louwman WJ, van der Sangen MJ, Roumen RM, Coebergh JW. Increased risk of second malignancies after in situ breast carcinoma in a population-based registry. Br J Cancer. 2006;95(3):393–7. Pubmed Central PMCID: 2360642, Epub 2006/06/29. eng.CrossRefPubMedPubMedCentral Soerjomataram I, Louwman WJ, van der Sangen MJ, Roumen RM, Coebergh JW. Increased risk of second malignancies after in situ breast carcinoma in a population-based registry. Br J Cancer. 2006;95(3):393–7. Pubmed Central PMCID: 2360642, Epub 2006/06/29. eng.CrossRefPubMedPubMedCentral
12.
go back to reference King TA, Pilewskie M, Muhsen S, Patil S, Mautner SK, Park A, et al. Lobular carcinoma in situ: a 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk. J Clin Oncol. 2015;33(33):3945–52.CrossRefPubMedPubMedCentral King TA, Pilewskie M, Muhsen S, Patil S, Mautner SK, Park A, et al. Lobular carcinoma in situ: a 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk. J Clin Oncol. 2015;33(33):3945–52.CrossRefPubMedPubMedCentral
13.
go back to reference Eusebi V, Feudale E, Foschini MP, Micheli A, Conti A, Riva C, et al. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol. 1994;11(3):223–35. Epub 1994/08/01. eng.PubMed Eusebi V, Feudale E, Foschini MP, Micheli A, Conti A, Riva C, et al. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol. 1994;11(3):223–35. Epub 1994/08/01. eng.PubMed
14.
go back to reference Warnberg F, Bergh J, Holmberg L. Prognosis in women with a carcinoma in situ of the breast: a population-based study in Sweden. Cancer Epidemiol Biomarkers Prev. 1999;8(9):769–74. Epub 1999/09/25. eng.PubMed Warnberg F, Bergh J, Holmberg L. Prognosis in women with a carcinoma in situ of the breast: a population-based study in Sweden. Cancer Epidemiol Biomarkers Prev. 1999;8(9):769–74. Epub 1999/09/25. eng.PubMed
15.
go back to reference Hemminki K, Granstrom C. Familial breast carcinoma risks by morphology: a nationwide epidemiologic study from Sweden. Cancer. 2002;94(11):3063–70. Epub 2002/07/13. eng.CrossRefPubMed Hemminki K, Granstrom C. Familial breast carcinoma risks by morphology: a nationwide epidemiologic study from Sweden. Cancer. 2002;94(11):3063–70. Epub 2002/07/13. eng.CrossRefPubMed
16.
go back to reference Stuart KE, Houssami N, Taylor R, Hayen A, Boyages J. Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis. BMC Cancer. 2015;15:890. Pubmed Central PMCID: 4641372.CrossRefPubMedPubMedCentral Stuart KE, Houssami N, Taylor R, Hayen A, Boyages J. Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis. BMC Cancer. 2015;15:890. Pubmed Central PMCID: 4641372.CrossRefPubMedPubMedCentral
17.
go back to reference Warnberg F, Bergh J, Zack M, Holmberg L. Risk factors for subsequent invasive breast cancer and breast cancer death after ductal carcinoma in situ: a population-based case–control study in Sweden. Cancer Epidemiol Biomarkers Prev. 2001;10(5):495–9. Epub 2001/05/16. eng.PubMed Warnberg F, Bergh J, Zack M, Holmberg L. Risk factors for subsequent invasive breast cancer and breast cancer death after ductal carcinoma in situ: a population-based case–control study in Sweden. Cancer Epidemiol Biomarkers Prev. 2001;10(5):495–9. Epub 2001/05/16. eng.PubMed
18.
go back to reference Falk RS, Hofvind S, Skaane P, Haldorsen T. Second events following ductal carcinoma in situ of the breast: a register-based cohort study. Breast Cancer Res Treat. 2011;129(3):929–38. Epub 2011/05/04. eng.CrossRefPubMed Falk RS, Hofvind S, Skaane P, Haldorsen T. Second events following ductal carcinoma in situ of the breast: a register-based cohort study. Breast Cancer Res Treat. 2011;129(3):929–38. Epub 2011/05/04. eng.CrossRefPubMed
19.
go back to reference Emdin SO, Granstrand B, Ringberg A, Sandelin K, Arnesson LG, Nordgren H, et al. SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol. 2006;45(5):536–43. Epub 2006/07/26. eng.CrossRefPubMed Emdin SO, Granstrand B, Ringberg A, Sandelin K, Arnesson LG, Nordgren H, et al. SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol. 2006;45(5):536–43. Epub 2006/07/26. eng.CrossRefPubMed
20.
go back to reference Claus EB, Petruzella S, Matloff E, Carter D. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA. 2005;293(8):964–9. Epub 2005/02/25. eng.CrossRefPubMed Claus EB, Petruzella S, Matloff E, Carter D. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA. 2005;293(8):964–9. Epub 2005/02/25. eng.CrossRefPubMed
21.
go back to reference Harris EE, Schultz DJ, Peters CA, Solin LJ. Relationship of family history and outcome after breast conservation therapy in women with ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys. 2000;48(4):933–41. Epub 2000/11/10. eng.CrossRefPubMed Harris EE, Schultz DJ, Peters CA, Solin LJ. Relationship of family history and outcome after breast conservation therapy in women with ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys. 2000;48(4):933–41. Epub 2000/11/10. eng.CrossRefPubMed
22.
go back to reference Ji J, Hemminki K. Risk for contralateral breast cancers in a population covered by mammography: effects of family history, age at diagnosis and histology. Breast Cancer Res Treat. 2007;105(2):229–36. Epub 2006/11/23. eng.CrossRefPubMed Ji J, Hemminki K. Risk for contralateral breast cancers in a population covered by mammography: effects of family history, age at diagnosis and histology. Breast Cancer Res Treat. 2007;105(2):229–36. Epub 2006/11/23. eng.CrossRefPubMed
23.
go back to reference Bradley SJ, Weaver DW, Bouwman DL. Alternatives in the surgical management of in situ breast cancer. A meta-analysis of outcome. Am Surg. 1990;56(7):428–32. Epub 1990/07/01. eng.PubMed Bradley SJ, Weaver DW, Bouwman DL. Alternatives in the surgical management of in situ breast cancer. A meta-analysis of outcome. Am Surg. 1990;56(7):428–32. Epub 1990/07/01. eng.PubMed
24.
go back to reference Rutqvist LE, Wallgren, A. Inconsistencies in breast carcinoma registration. An investigation of 855 cases reported to the Swedish Cancer Registry. Acta Radiol Oncol. 1983;22(2):109–12.CrossRefPubMed Rutqvist LE, Wallgren, A. Inconsistencies in breast carcinoma registration. An investigation of 855 cases reported to the Swedish Cancer Registry. Acta Radiol Oncol. 1983;22(2):109–12.CrossRefPubMed
25.
go back to reference Mattsson B, Wallgren A. Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol. 1984;23(5):305–13.CrossRefPubMed Mattsson B, Wallgren A. Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol. 1984;23(5):305–13.CrossRefPubMed
26.
go back to reference Garne JP, Aspegren K, Moller T. Validity of breast cancer registration from one hospital into the Swedish National Cancer Registry 1971–1991. Acta Oncol. 1995;34(2):153–6.CrossRefPubMed Garne JP, Aspegren K, Moller T. Validity of breast cancer registration from one hospital into the Swedish National Cancer Registry 1971–1991. Acta Oncol. 1995;34(2):153–6.CrossRefPubMed
27.
go back to reference Breslow NE, Day NE, editors. Statistical Methods in Cancer Research. Lyon: Volume II: The design and analysis of cohort studies; 1987. Breslow NE, Day NE, editors. Statistical Methods in Cancer Research. Lyon: Volume II: The design and analysis of cohort studies; 1987.
28.
go back to reference Collaborative Group on Hormonal Factors in Breast cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001;358(9291):1389–99. Epub 2001/11/14. eng. Collaborative Group on Hormonal Factors in Breast cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001;358(9291):1389–99. Epub 2001/11/14. eng.
29.
go back to reference Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer. 1997;71(5):800–9.CrossRefPubMed Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer. 1997;71(5):800–9.CrossRefPubMed
30.
go back to reference Olsson S, Andersson I, Karlberg I, Bjurstam N, Frodis E, Hakansson S. Implementation of service screening with mammography in Sweden: from pilot study to nationwide programme. J Med Screen. 2000;7(1):14–8.CrossRefPubMed Olsson S, Andersson I, Karlberg I, Bjurstam N, Frodis E, Hakansson S. Implementation of service screening with mammography in Sweden: from pilot study to nationwide programme. J Med Screen. 2000;7(1):14–8.CrossRefPubMed
31.
go back to reference Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet. 2002;359(9310):909–19.CrossRefPubMed Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet. 2002;359(9310):909–19.CrossRefPubMed
33.
go back to reference Julien JP, Bijker N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet. 2000;355(9203):528–33. Epub 2000/02/22. eng.CrossRefPubMed Julien JP, Bijker N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet. 2000;355(9203):528–33. Epub 2000/02/22. eng.CrossRefPubMed
34.
go back to reference Holmberg L, Garmo H, Granstrand B, Ringberg A, Arnesson LG, Sandelin K, et al. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol. 2008;26(8):1247–52. Epub 2008/02/06. eng.CrossRefPubMed Holmberg L, Garmo H, Granstrand B, Ringberg A, Arnesson LG, Sandelin K, et al. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol. 2008;26(8):1247–52. Epub 2008/02/06. eng.CrossRefPubMed
35.
go back to reference Fisher B, Costantino J, Redmond C, Fisher E, Margolese R, Dimitrov N, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med. 1993;328(22):1581–6. Epub 1993/06/03. eng.CrossRefPubMed Fisher B, Costantino J, Redmond C, Fisher E, Margolese R, Dimitrov N, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med. 1993;328(22):1581–6. Epub 1993/06/03. eng.CrossRefPubMed
36.
go back to reference Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998;16(2):441–52. Epub 1998/02/20. eng.PubMed Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998;16(2):441–52. Epub 1998/02/20. eng.PubMed
37.
go back to reference Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362(9378):95–102. Epub 2003/07/18. eng.CrossRefPubMed Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362(9378):95–102. Epub 2003/07/18. eng.CrossRefPubMed
38.
go back to reference Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014;383(9922):1041–8.CrossRefPubMed Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014;383(9922):1041–8.CrossRefPubMed
39.
go back to reference Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364(25):2381–91.CrossRefPubMed Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364(25):2381–91.CrossRefPubMed
40.
go back to reference Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res. 2010;3(6):696–706. Pubmed Central PMCID: 2935331.CrossRef Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res. 2010;3(6):696–706. Pubmed Central PMCID: 2935331.CrossRef
41.
go back to reference Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–88.CrossRefPubMed Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–88.CrossRefPubMed
42.
go back to reference Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol. 2012;30(12):1268–73. Pubmed Central PMCID: 3341142.CrossRefPubMedPubMedCentral Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol. 2012;30(12):1268–73. Pubmed Central PMCID: 3341142.CrossRefPubMedPubMedCentral
43.
go back to reference Staley H, McCallum I, Bruce J. Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis. Breast. 2014;23(5):546–51.CrossRefPubMed Staley H, McCallum I, Bruce J. Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis. Breast. 2014;23(5):546–51.CrossRefPubMed
Metadata
Title
The impact of in situ breast cancer and family history on risk of subsequent breast cancer events and mortality - a population-based study from Sweden
Authors
Helena Sackey
Miao Hui
Kamila Czene
Helena Verkooijen
Gustaf Edgren
Jan Frisell
Mikael Hartman
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2016
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-016-0764-7

Other articles of this Issue 1/2016

Breast Cancer Research 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine